Cue Biopharma (CUE) Insider Trading & Ownership $1.10 -0.02 (-1.79%) As of 02:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Cue Biopharma (NASDAQ:CUE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage12.26%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$30,900.00Number OfInsiders Selling(Last 12 Months)0 Get CUE Insider Trade Alerts Want to know when executives and insiders are buying or selling Cue Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CUE Insider Buying and Selling by Quarter Cue Biopharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/16/2024Daniel R PasseriCEOBuy30,000$1.03$30,900.00 (Data available from 1/1/2013 forward) CUE Insider Trading Activity - Frequently Asked Questions Who is on Cue Biopharma's Insider Roster? The list of insiders at Cue Biopharma includes Aaron G.L. Fletcher, Anish Suri, Daniel R Passeri, and Peter A Kiener. Learn more on insiders at CUE. What percentage of Cue Biopharma stock is owned by insiders? 12.26% of Cue Biopharma stock is owned by insiders. Learn more on CUE's insider holdings. Which Cue Biopharma insiders have been buying company stock? The following insiders have purchased CUE shares in the last 24 months: Anish Suri ($11,040.00), and Daniel R Passeri ($39,480.00). How much insider buying is happening at Cue Biopharma? Insiders have purchased a total of 37,000 CUE shares in the last 24 months for a total of $50,520.00 bought. Which Cue Biopharma insiders have been selling company stock? The following insider sold CUE shares in the last 24 months: Peter A Kiener ($30,586.00). How much insider selling is happening at Cue Biopharma? Insiders have sold a total of 9,325 Cue Biopharma shares in the last 24 months for a total of $30,586.00 sold. Cue Biopharma Key ExecutivesMr. Daniel R. Passeri J.D. (Age 63)M.Sc., CEO & Director Compensation: $607.98k1 recent tradesDr. Anish Suri Ph.D. (Age 50)President & Chief Scientific Officer Compensation: $447.34kMs. Kerri-Ann Millar (Age 54)Chief Financial Officer Compensation: $447.34kDr. Ronald D. Seidel III (Age 48)Ph.D., Co-Founder Compensation: $316.63kMr. Colin G. Sandercock J.D. (Age 67)MSE, Senior VP, General Counsel & Secretary Compensation: $381.42kDr. Matteo Levisetti M.D. (Age 55)Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies REGENXBIO Insider Selling Prime Medicine Insider Selling Benitec Biopharma Insider Selling Terns Pharmaceuticals Insider Selling Atyr PHARMA Insider Selling Acelyrin Insider Selling Septerna Insider Selling Gossamer Bio Insider Selling DiaMedica Therapeutics Insider Selling Rapport Therapeutics Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 2 Stocks Insiders Are Buying and 1 They're Selling3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q4 This page (NASDAQ:CUE) was last updated on 3/6/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s Oil Play: Smart Move, Bad PayoutBuffett's making a massive bet on oil with Occidental. But investors only get 1.3% in dividends… That's ...Investors Alley | Sponsored77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredTrillion-Dollar Crypto PlayAI is Creating Fortunes… (but not where you think!) Bryce Paul and the team at Crypto101 just released a br...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
